Mirum Pharmaceuticals, Inc.
Brelovitug 300 mg
Chronic Hepatitis D Infection
Countdown
56days
Phase 3 readout · ~ Aug 31, 2026 estimated
What's at stake
Phase 3 trial results for Brelovitug 300 mg in Chronic Hepatitis D Infection are due ~ Aug 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT07298330: Phase 3 trial, sponsor Mirum Pharmaceuticals, Inc., drug Brelovitug 300 mg. Primary completion date 2026-08 (estimated).”